Bangying Su

Corporate Officer/Principal bei Washington University in St. Louis

Consumer Services

Health Technology

Profil

Bangying Su is currently a Principal at Washington University in St. Louis and a Principal at The University of Alabama.
Previously, Dr. Su worked as a Scientist at Dynamis Therapeutics, Inc. Dr. Su completed their undergraduate degree at Peking University.

Aktive Positionen von Bangying Su

Unternehmen	Position	Beginn
Washington University in St. Louis	Corporate Officer/Principal	25.01.2010
The University of Alabama	Corporate Officer/Principal	25.01.2010

Alle aktiven Positionen von Bangying Su

Ehemalige bekannte Positionen von Bangying Su

Unternehmen	Position	Ende
Dynamis Therapeutics, Inc. Dynamis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Dynamis Therapeutics, Inc. operates as a holding company with interests in developing pharmaceuticals and diagnostics. It operates through its subsidiaries Dynamis Pharmaceuticals, Inc. and Dynamis Skin Science. The firm's product DYN 15, a drug candidate that prevents the formation of 3DG, a reactive sugar, as well as decreases the levels of key cytokines that are stimulated in chronic inflammations. The company was founded by Annette M. Tobia on May 21, 1997 and is headquartered in Jenkintown, PA.	Corporate Officer/Principal	-

Sehen Sie sich die Erfahrung von Bangying Su im Detail an

Ausbildung von Bangying Su

Peking University

Undergraduate Degree

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Bangying Su im Detail an

Beziehungen

100 +

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	1
Dynamis Therapeutics, Inc. Dynamis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Dynamis Therapeutics, Inc. operates as a holding company with interests in developing pharmaceuticals and diagnostics. It operates through its subsidiaries Dynamis Pharmaceuticals, Inc. and Dynamis Skin Science. The firm's product DYN 15, a drug candidate that prevents the formation of 3DG, a reactive sugar, as well as decreases the levels of key cytokines that are stimulated in chronic inflammations. The company was founded by Annette M. Tobia on May 21, 1997 and is headquartered in Jenkintown, PA.	Health Technology